Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Slides:



Advertisements
Similar presentations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.
Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.
Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,
Volume 14, Issue 8, Pages (December 2011)
Value in Health Regional Issues
Volume 18, Issue 5, Pages (July 2015)
Mapping the COPD Assessment Test onto EQ-5D
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Volume 17, Issue 2, Pages (March 2014)
Volume 18, Issue 4, Pages (June 2015)
Volume 14, Issue 4, Pages (June 2011)
Volume 18, Issue 8, Pages (December 2015)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 17, Issue 8, Pages (December 2014)
Volume 14, Issue 4, Pages (June 2011)
Volume 15, Issue 6, Pages (September 2012)
Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores 
Volume 15, Issue 1, Pages (January 2012)
Volume 19, Issue 5, Pages (July 2016)
Volume 17, Issue 2, Pages (March 2014)
Examining the Value of Menopausal Symptom Relief Among US Women
Volume 17, Issue 2, Pages (March 2014)
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Value in Health Regional Issues
The Process of Privatization of Health Care Provision in Poland
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
The Living with Medicines Questionnaire: Translation and Cultural Adaptation into the Arabic Context  Amani Zidan, BScPharm, Ahmed Awaisu, PhD, Sanah.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India  S.K.R. Sowmya, PharmD, Dixon.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach  Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan
Value in Health Regional Issues
The Economic Impact of Cigarette Smoking on the Poor in Jordan
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD 
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China  Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,
Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program  Manabu Akazawa,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Value in Health Regional Issues
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Value in Health Regional Issues
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Social Cost of Substance Abuse in Russia
Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia  Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
Economic Burden of Incident Unplanned Starts on Peritoneal Dialysis in a High Specialty Health Care Facility in Mexico City  Sergio O. Hdez Ordonez, MD,
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates  Christina X. Chen, PhD, Judith R. Baker, DrPH, Michael B. Nichol, PhD  Value in Health  Volume 20, Issue 8, Pages 1074-1082 (September 2017) DOI: 10.1016/j.jval.2017.04.017 Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Mean annual nonfactor health care services utilization costs by HB severity and treatment regimen. This excludes participants with inhibitors (n = 2). Numeric labels above bars represent total mean per-person health care services utilization costs. Error bars represent 95% confidence intervals for total per-person health care services utilization costs. ER, emergency room; HB, hemophilia B; HTC, hemophilia treatment center. Value in Health 2017 20, 1074-1082DOI: (10.1016/j.jval.2017.04.017) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Mean annual indirect costs by HB severity and treatment regimen. This excludes participants with inhibitors (n = 2). Numeric labels above bars represent total mean per-person indirect costs. Error bars represent 95% confidence intervals for total per-person indirect costs. HB, hemophilia B. Value in Health 2017 20, 1074-1082DOI: (10.1016/j.jval.2017.04.017) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.